GYRE

#2649
Gyre Therapeutics, Inc. - Common Stock
6.8 4 USD
+0.06%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
6.77
6.89
Jahresspanne
5.44
9.14
Tagesänderung
+6.21%
Monatliche Änderung
+10.50%
6 month change
-21.20%
Jahresänderung
-17.19%
Vorheriger Schlusskurs
6.4 4
Open
6.7 7
Tief
6.7 7
Hoch
6.8 9
Volumen
26
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, 01 Sep 2026
GYRE THERAPEUTICS, INC. current report, 01 September 2026
8-K
Current report, 26 Aug 2026
GYRE THERAPEUTICS, INC. current report, 26 August 2026
8-K
Current report, Q3 FY2026
GYRE THERAPEUTICS, INC. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
GYRE THERAPEUTICS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
GYRE THERAPEUTICS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
GYRE THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GYRE THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GYRE THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GYRE THERAPEUTICS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
GYRE THERAPEUTICS, INC. current report, Q2 FY2026
8-K

GYRE THERAPEUTICS, INC. current report, Q1 FY2025

Full document

Business Context and Reporting Period

Company: Gyre Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 17, 2025
Reporting Period: Fourth quarter and full year ended December 31, 2024.
Context: This filing serves as a notification that the company issued a press release on March 17, 2025, announcing its financial results for the specified period. The detailed financial data is contained within the press release furnished as Exhibit 99.1.

Key Financial Metrics

The provided Form 8-K text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being detailed in the press release (Exhibit 99.1) but are not explicitly stated in the body of this current report.

Material Changes

No specific material changes regarding financial performance or operational status are detailed in the text of this filing. The filing indicates that such information is available in the accompanying press release.

Guidance, Outlook, and Risks

Management Commentary: The filing notes the issuance of a press release covering financial results and "other matters described," but does not summarize the content of that commentary.
Forward-Looking Statements: The filing includes standard disclaimers stating that the information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Risks and Contingencies: No specific risks or contingencies are listed in the text of this 8-K.

Investor Verification Checklist

  • Review Exhibit 99.1 (Press Release dated March 17, 2025) for specific Q4 and full-year 2024 financial figures.
  • Verify the "other matters" referenced in the press release announcement for potential operational updates.
  • Confirm the company's cash position and runway, as these are critical for a biotechnology firm but are not detailed in this summary filing.
  • Check for any subsequent filings that may incorporate the press release by reference.